Publications
188
Citations
3,897
Est. group size
~4
Recurring co-author estimate
Active years
23
Publishing since 2004
This researcher studies cancer biology with a focus on ovarian and pancreatic cancers, examining molecular signaling pathways (such as STAT3/PIAS3), extracellular vesicles (small particles cells release that can carry signals to other cells), and microRNAs (small molecules that regulate gene activity) as potential biomarkers and drug targets. Much of the work explores how these mechanisms relate to cancer development, diagnosis, and potential treatments, including a STAT3-inhibiting compound tested in ovarian cancer. This profile would suit students interested in cancer cell signaling, biomarker discovery, or translational cancer therapeutics.
Publication counts were low and steady (3-6 per year) from 2017-2022, followed by a large spike in 2023 (likely reflecting multiple supplementary data records from a single study) before returning to a more modest but slightly elevated level in 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Obesity-driven extracellular vesicle signaling in cancer: mechanistic insights and clinical implications
Oncogenesis · 2026
- Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma
Gastro Hep Advances · 2024
- Cancer stem cell–derived exosomes: what is known to date
Elsevier eBooks · 2023
- Supplementary Tables 1-3 from <i>STAT3/PIAS3</i> Levels Serve as “Early Signature” Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube
2023
- Supplementary Tables 1-3 from <i>STAT3/PIAS3</i> Levels Serve as “Early Signature” Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube
2023
- Data from <i>STAT3/PIAS3</i> Levels Serve as “Early Signature” Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube
2023
- Data from <i>STAT3/PIAS3</i> Levels Serve as “Early Signature” Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube
2023
- Supplementary Figures 1-11 from <i>STAT3/PIAS3</i> Levels Serve as “Early Signature” Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube
2023
- Supplementary Figures 1-11 from <i>STAT3/PIAS3</i> Levels Serve as “Early Signature” Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube
2023
- Data from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023
- Supplementary Methods from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023
- Supplementary Figure 9 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023
- Supplementary Figure 3 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023
- Supplementary Figure 6 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023
- Supplementary Figure 8 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023
- Cancer Research×12
- Gynecologic Oncology×5
- Oncogene×3
- Journal of Ovarian Research×2
- Handbook of Oxidative Stress in Cancer: Therapeutic Aspects×2
- Lianbo Yu
Medicine · The Ohio State University
- Pui‐Kai Li
Medicine · The Ohio State University
- Kathryn L. Terry
Medicine · The Ohio State University
- D. E. Cohn
Medicine · The Ohio State University
- Kalpana Deepa Priya Dorayappan
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile